Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Claims
Claims 31-32, 34, 46-47, 65, 73, 76, and 84 are pending as of the response and amendments filed on 8/5/26. Claims 1-30, 33, 35-45, 48-64, 66-72, 74-75, 77-83, and 85 have been canceled.
The rejections under 35 USC 112(b) and 102(a)(1) of record are withdrawn in view of the amendments.
The 102(a)(2) and 103 rejections of record are withdrawn as Applicants have stated the subject matter disclosed in WO 2022198232 was commonly owned by Seagan Inc. not later than the effective filing date of the claimed invention.
In view of the amendments, new rejections are made under 35 USC 112(b), discussed below.
Claims 31-32, 34, 46-47, 65, 73, 76, and 84 were examined. Claims 46, 65, 73, and 84 are rejected. Claims 31-32, 34, 47, and 76 are allowed.
Claim Rejections-35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 46, 65, 73, and 84 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
The second page of claim 46 recites “a maleimide moiety ….”, but doesn’t recite which variable corresponds to this moiety. It appears that some of the claim language is missing from this portion. As it’s uncertain what the maleimide moiety corresponds to, the claim is indefinite.
Claim 65 contains the group Rb6 as an attachment group for Formula D0b, however, the definition of Rb6 has been deleted from the amended claim. Therefore, the claim scope is indefinite, as it’s uncertain what functional group(s) constitute Rb6. Claims 73 and 84 are rejected as these claims depend from claim 65.
Reasons for Allowable Subject Matter
The following is a statement of reasons for the indication of allowable subject matter: the camptothecin derivatives of the claims are not taught or suggested by the prior art. Ryan et. al., WO 2012125232 A1 (publ. 9/20/2012) represents the most relevant prior art. Ryan teaches campothecin derivatives and camptothecin linker conjugates, and teaches the camptothecin core of the following formula:
PNG
media_image1.png
200
400
media_image1.png
Greyscale
, wherein n is 0 or 1, and R3 and R4 can together form a 5- or 6-membered ring. However, Ryan only provides guidance in which R3 and R4 form rings having two ring oxygen atoms, which are excluded by the instant claims. Additionally, Ryan doesn’t provide sufficient guidance to arrive at the specific selection of camptothecin substituents as claimed, or camptothecin-linker conjugates having one of the recited formulas as claimed.
Information Disclosure Statements
The IDS filed on 8/6/26 have been considered.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Correspondence
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached Monday-Friday 9:00-5:30 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
SARAH . PIHONAK
Primary Examiner
Art Unit 1627
/SARAH PIHONAK/Primary Examiner, Art Unit 1627